2. Peptides
  3. Peptide and Derivatives
  4. Peptides for Drug Delivery
  5. Cell-penetrating Peptides

Cell-penetrating Peptides

Custom Peptide Synthesis

Cell-penetrating peptides (CPPs) are short peptides that can cross cell membranes and facilitate cellular uptake of molecules. They have been widely applied as therapeutic and theranostic cargoes.

Cell-penetrating Peptides (144):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4108
    TAT-HA2 Fusion Peptide 923954-79-4 99.70%
    TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide is a transactivator of transcription and hemaglutanin for endosomal release. TAT-HA2 Fusion Peptide enhances cellular uptake of macromolecules.
    TAT-HA2 Fusion Peptide
  • HY-P1351
    Angiopep-2-Cys 906480-09-9 99.94%
    Angiopep-2-cys is a conjugate of Angiopep-2 hydrochloride (HY-P2341) and cysteine. Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer.
    Angiopep-2-Cys
  • HY-P10152
    INF7 185462-59-3
    INF7 is a derivative of the N-terminal domain of the HA2 protein and is sensitive to pH. INF7 disrupts the stability of endosomal membranes through a mechanism independent of membrane fusion. INF7 can be used to enhance the endosome escape of complex or liposome-encapsulated proteins. Co-encapsulation of INF7 and molecular imaging probes in liposomes can enhance intracellular signaling and probe retention.
    INF7
  • HY-P5307
    Peptide A5K 99.34%
    Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy.
    Peptide A5K
  • HY-P0281
    TAT 191936-91-1 99.92%
    TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins.
    TAT
  • HY-P4099A
    Cys(Npys)-(D-Arg)9 TFA 99.07%
    Cys(Npys)-(D-Arg)9 TFA is an amphipathic R9 cell penetrating peptide (CPP). Cys(Npys)-(D-Arg)9 TFA has cytotoxicity for microspore cells with the amount higher than 1 nmol.
    Cys(Npys)-(D-Arg)9 TFA
  • HY-P4104A
    pVEC-Cys
    pVEC-Cys
  • HY-P4076A
    MPG-Cys 3068018-53-8
    MPG-Cys
  • HY-P5623A
    RVG-Cys 1186105-01-0 99.95%
    RVG-Cys (RVG29-Cys) is a peptide derived from rabies virus glycoprotein (RVG29) with Cys attached to facilitate subsequent conjugation. RVG-Cys enhances the specific targeted delivery of proteins in brain tissue and neurons.
    RVG-Cys
  • HY-P0282A
    TAT peptide TFA 99.83%
    TAT peptide (TFA) is a cell penetrating peptide (GRKKRRQRRRPQ) derived from the trans-activating transcriptional activator (Tat) from HIV-1.
    TAT peptide TFA
  • HY-P2529
    Penetratin 940866-75-1 99.98%
    Penetratin is a cell-penetrating peptides derived from a nonviral protein. Penetratin can powerfully enhance drug absorption. Penetratin can be used for drug delivery research in the treatment of various diseases.
    Penetratin
  • HY-P1876B
    NLS (PKKKRKV) (hydrochloride) 99.39%
    NLS (PKKKRKV) hydrochloride is the hydrochloride form of NLS (PKKKRKV) (HY-P1876). NLS (PKKKRKV) is a nuclear localization signal (NLS) derived from the simian virus 40 large tumor antigen (SV40 large T antigen), that mediates binding of the karyophilic protein to importin α. NLS (PKKKRKV) can function as a method to enhance nuclear entry in the field of gene transfer research.
    NLS (PKKKRKV) (hydrochloride)
  • HY-P5284
    RALA peptide 1613231-49-4 99.16%
    RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization).
    RALA peptide
  • HY-P10068
    LAH5 476169-12-7 99.32%
    LAH5 is an amphipathic cell-penetrating peptide. LAH5 forms nanocomplexes with both RNP and RNP/HDR cargo.
    LAH5
  • HY-P1848
    Pep-1 (uncapped) 395069-86-0 99.89%
    Pep-1 (uncapped) is a specific ligand of IL-13Ra2. Pep-1 (uncapped) exerts cell penetrating activity through receptor-mediated endocytosis, can cross the blood-tumor barrier (BTB) and target glioma cells. Pep-1 (uncapped) can enhance the uptake of nanoparticles by tumor cells and enhance the cell penetration ability of nanoparticles, and can be used to develop targeted drug delivery systems for glioma.
    Pep-1 (uncapped)
  • HY-P4121
    L17E 1898254-09-5 99.88%
    L17E is an attenuated cationic amphiphilic lytic (ACAL) peptide that can be used to deliver a variety of macromolecules, including proteins, antibodies, and DNA nanostructures. L17E inserts and cleaves the membrane structure through electrostatic interaction, enabling intracellular escape. The efficiency of L17E-mediated delivery is strongly correlated with the expression level of KCNN4 (the gene encoding the calcium-activated potassium channel KCa3.1). L17E also promotes the cellular uptake of macromolecules by inducing micropinocytosis. L17E can be further optimized and improved through dimerization strategies and in combination with other delivery systems, such as nuclear localization signal peptides and cell membrane-coated nanoparticles.
    L17E
  • HY-P5623
    RVG 115136-25-9 99.81%
    RVG (RVG29) is a blood-brain barrier-permeable peptide derived from rabies virus glycoprotein, which binds to the α-7 subunit of neuronal nicotinic acetylcholine receptor (AchR). RVG efficiently delivers drugs to nerve cells and antigen-presenting cells in a targeted manner, and enhances the efficiency of antigen presentation and drug delivery.
    RVG
  • HY-P0133B
    (Arg)9 acetate 99.89%
    (Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.
    (Arg)9 acetate
  • HY-P11072
    IRF5-CPP5 1601299-92-6 99.23%
    IRF5-CPP5 is a cytosolic peptide that selectively targeting human IRF5 wirh a Kd of 0.53 μM. IRF5-CPP5 disrupts IRF5 homodimerization and inhibits its nuclear translocation without altering IRF5 phosphorylation levels. IRF5-CPP5 inhibits proinflammatory cytokine (IL-6, IL-1β, TNF-α) production. IRF5-CPP5 can be used for the research of systemic lupus erythematosus.
    IRF5-CPP5
  • HY-P1801A
    Cys-TAT(47-57) TFA 98.33%
    Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) TFA, TAT (HY-P0281) derivative, is a Cysteine (HY-Y0337)-tagged cell-penetrating peptide (CPP) derived from the HIV TAT protein. Cys-TAT(47-57) TFA can be used for the research for the research of drug delivery.
    Cys-TAT(47-57) TFA